ArticleCommunications biology2026
Downfield magnetic resonance signals serve as endogenous imaging biomarkers of nucleotide metabolism in glioma.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gliomas, the most common primary brain tumors, exhibit profound metabolic alterations that can be non-invasively probed using magnetic resonance spectroscopy (MRS). Compared to upfield signals in traditional MRS, downfield signals exhibit complex composition with limited understanding of their metabolite origins. Correlating high-throughput metabolic profiles provided by untargeted metabolomics with MRS signals can help elucidate the origins of metabolites in MRS. In this study, upfield and downfield MRS spectra are obtained from control and glioma-bearing male Wistar rats, followed by correlation analysis with untargeted metabolomics from corresponding brain tissues. Here, we show that multiple downfield MRS peaks are significantly elevated in glioma rats and correlate with metabolomic features. Notably, downfield MRS demonstrate the capability of capturing adenosine triphosphate (ATP)-associated nucleotide metabolism. Furthermore, MRS signatures exhibit predictive potential for tumor growth parameters. This work establishes an integrated MRS-metabolomics framework, providing a basis for non-invasively monitoring dynamic metabolic reprogramming and predicting glioma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.